[ad_1]
Although the drug has not yet been produced, the results of studies with this molecule, until the end of the (19659002) "It has great potential for, in the future, we can have a new drug against malaria, "said Professor Rafael Victorio Carvalho Guido of the Institute of Physics of São Carlos (IFSC)
Developed tests show that the molecule is able to kill the parasite, and even the strain, which has resisted the current drugs used in the treatment of the disease. malaria
The study is the result of collaboration. In addition to Rafael Guido, Célia Garcia teachers participate in the research. Glaucius Oliva, USP of São Carlos, and Carlos Roque Duarte Correia, University of Campinas State (Unicamp), among other collaborators
The Molecule
Research has shown that the molecule, derived from the clbad of marinoquinolines, showed selectivity and low toxicity, acting on the parasite [o protozoário causador da malária] and not on any other host cells.
It was developed at the Center for Research and Innovation in Biodiversity. (CIBFar) – Center for Research, Innovation and Dissemination (Cepid) funded by FAPESP
The study also received financial support from the National Council for Scientific and Technological Development (CNPq) and from the Instituto Serrapilheira
. Professor Roque is already working with a clbad of molecules, marine natural products, marine bacteria, called marinoquinolines, and a "
However, natural products have had a moderate or low action against pathogens." But for this study, the power of the molecules has been increased.
"We need a molecule capable of killing the parasite and being a candidate, and we finally got a pretty potent molecule, low concentration, c & # 39; That is, a small amount that would kill the parasite, "said Guido.
" And more importantly, we managed to make the molecule selective, kill the parasite without killing "
39, study, the researchers began to observe that, moreover, this molecule also had another advantage: it acted on more than one form of parasite.
to see that this molecule has not only killed this form [de parasita] who was in the blood, but also killed the form that was in the liver, "said the professor.
The molecule has also managed to kill resistant strains in the main is drugs. Currently, the most widely used drug in the treatment of malaria is artemisinin, which, although effective, already exists over the years.
"Although we have a treatment for this disease, and it is effective, we have already begun to observe the emergence of strains resistant to this drug," says Guido
It is then that the researchers discovered another benefit of the molecule. "We have been able to see that malaria, because it is a parasite that has existed for a long time, is able to generate resistance to currently used drugs."
Therefore, we need new treatments.
And we were able to show that this molecule could also kill these resistant parasites. "
Thus, Guido pointed out, there is a powerful molecule to kill the parasite that killed the resistant and was quite selective
Tests
Up to now, studies have been done in the laboratory and tested in mice with malaria
Studies have been conducted on malaria caused by the protozoan Plasmodium falciparum. "The untreated group [de camundongos doentes] died about 15 or 20 days.
And the mice that were treated survived during the 30 days of experimentation, showing that the molecule was well tolerated by the body and did not become toxic.
And the treated group, in addition to surviving during this time of study, had a reduction in the parasite load in the blood, "said the professor, speaking of the results of the tests on the
Several steps are still needed – and years of study and testing – for the drug to be tested in humans and produced.
Studies up to here have been developed in the most lethal form of malaria and still have to be evaluated with other protozoan forms, such as
"We have not yet published these results, but we could see that this molecule can also kill the vivax. "
According to Guido, another necessary step is to develop the pharmacokinetic part of the project – the body's reaction to the drug, that is to say, improve the characteristics of this molecule so that it can be administered orally e
"It must enter our body, be absorbed by the intestine and be distributed – because the parasite is in the whole blood, be metabolized, eliminated, excreted. We improve these characteristics of molecules. "
" If you could do that, you would have a preclinical candidate, and then we would go to clinical trials.
He recalled, however, that all these processes and
Malaria
Malaria is an acute febrile infectious disease caused by protozoa transmitted by the female infected with the Anopheles mosquito
. Health, everyone can contract malaria, but it is possible to cure if the disease is treated in a timely and appropriate manner, but malaria can progress to a severe form and death
.Malaria-related malaria is a strong fever, chills, chills, sweats and headaches, which can occur cyclically Many people experience nausea, vomiting, fatigue and a lack of appetite [19659002] World Health Organization (WHO), the disease currently kills 445,000 people each year.
"By dividing this number by the number of minutes in the year, we perceive the reason [quase] of A d [por malária] every minute, "said Guido
Malaria is the most common killer disease in the world. "If we do nothing today, he will kill many more in a few years," he added.
Most deaths occur in Africa, most of them children. According to the professor, among those who die, 75% are children. "This study has a huge social impact," he said.
[ad_2]
Source link
